Bradyarrhythmias secondary to topical levobunolol hydrochloride solution
- PMID: 25342892
- PMCID: PMC4206249
- DOI: 10.2147/CIA.S69420
Bradyarrhythmias secondary to topical levobunolol hydrochloride solution
Abstract
An 88-year-old man was admitted with fatigue, dizziness, and heart palpitations. Both the electrocardiogram and Holter confirmed the existence of sinus bradycardia and sinus arrest. One hour prior to the onset of symptoms, he received levobunolol hydrochloride solution topically. The levobunolol hydrochloride solution was discontinued and the bradycardia resolved. He was diagnosed as having intermittent sinus bradycardia and sinus arrest, induced by topical β-blocker therapy. Levobunolol hydrochloride solution is an effective therapy for ocular hypertension, probably by reducing aqueous fluid production. However, it can induce cardiac side effects such as bradyarrhythmia and should be used with caution in elderly patients or patients with cardiac disease.
Keywords: bradycardia; glaucoma; the elderly; topical β-blocker.
Figures



Similar articles
-
Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension.Clin Ther. 1998 Nov-Dec;20(6):1170-8. doi: 10.1016/s0149-2918(98)80112-4. Clin Ther. 1998. PMID: 9916610 Clinical Trial.
-
A comparison of the efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD and 0.5% levobunolol hydrochloride BID in patients with ocular hypertension or open-angle glaucoma.J Ocul Pharmacol Ther. 2002 Apr;18(2):105-13. doi: 10.1089/108076802317373860. J Ocul Pharmacol Ther. 2002. PMID: 12002664 Clinical Trial.
-
Efficacy and safety of once-daily levobunolol for glaucoma therapy.Can J Ophthalmol. 1989 Feb;24(1):2-6. Can J Ophthalmol. 1989. PMID: 2653592 Clinical Trial.
-
Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade.Heart Dis. 2001 Nov-Dec;3(6):386-97. doi: 10.1097/00132580-200111000-00007. Heart Dis. 2001. PMID: 11975823 Review.
-
Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension.J Clin Pharmacol. 1994 Aug;34(8):795-803. doi: 10.1002/j.1552-4604.1994.tb02042.x. J Clin Pharmacol. 1994. PMID: 7962666 Review.
Cited by
-
Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates.Pharmaceuticals (Basel). 2021 Oct 26;14(11):1084. doi: 10.3390/ph14111084. Pharmaceuticals (Basel). 2021. PMID: 34832866 Free PMC article. Review.
-
The Effect of β-Blocker Eye Drops on Pulse Rate, Ocular Blood Flow, and Glaucoma Progression: A Retrospective Longitudinal Study.Adv Ther. 2024 Feb;41(2):730-743. doi: 10.1007/s12325-023-02762-0. Epub 2024 Jan 2. Adv Ther. 2024. PMID: 38169060 Free PMC article.
References
-
- Koch-Weser J, Frishman WH. beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981;305(9):500–506. - PubMed
-
- Yablonski ME, Novack GD, Burke PJ, Cook DJ, Harmon G. The effect of levobunolol on aqueous humor dynamics. Exp Eye Res. 1987;44(1):49–54. - PubMed
-
- Derick RJ, Robin AL, Tielsch J, et al. Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study. Ophthalmology. 1992;99(3):424–429. - PubMed
-
- Rakofsky SI, Melamed S, Cohen JS, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. Ophthalmology. 1989;96(1):8–11. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources